Table 6: Major Studies of Pharmacologic Treatment in ISH

Table 6:
Major Studies of Pharmacologic Treatment in ISH
	SHEP	Syst-EUR	Syst-China
Design	Double blind	Double blind	Single blind
Patients	4736	4695	2394
Age	60+	60+	60+
SBP/DBP Start (tx)	160-219/< 90	160-219/< 90	160-219/< 90
Drug (1^st)	Chlorthalidone	Nitrendipine	Nitrendipine
Drug (2^nd)	Atenalol	Enalapril	Captopril
Drug (3^rd)	Reserpine	Hydrochlorothiazide	Hydrochlorothiazide
Significant End Points	Total stroke reduced by 36%; nonfatal stroke by 37%; nonfatal MI by 33%; nonfatal MI + coronary death by 27%; nonfatal LV failure by 54%; all major cardiovascular complications by 32%	Total stroke reduced by 42%; nonfatal stroke by 44%; all fatal and nonfatal cardiac end points by 26%; nonfatal cardiac end points by 33%	Total stroke reduced by 38%; all-cause mortality by 39%; cardiovascular mortality by 39%; stroke mortality by 58%; all fatal and nonfatal cardiovascular end points by 37%
SHEP=Systolic Hypertension in the Elderly Program; Syst-EUR=Systolic Hypertension in Europe; Syst-China=Systolic Hypertension in China; MI=Myocardial infarction